Grant ID

02T-134

Illness

Bipolar Disorder and Schizophrenia

Primary Drug/Intervention

Orlistat

Primary Dosage

120 mg tid

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Joffe

Sample Size

80

Duration of Study Period for Each Subject

16 weeks

Outcome Measurements

Body weight, metabolic measurements

Results

Seventy-one patients taking clozapine or olanzapine, with body mass index 28-43 kg/m², were randomized to receive adjunctive orlistat or placebo. Sixty-three patients completed the study. No significant differences were observed between drug and placebo for body weight, serum glucose, or serum lipids. In a secondary analysis, male patients randomized to orlistat had a significant reduction in body weight (~3 kg greater than with placebo).

Publication

N/A

Link

N/A

PI Name

Grigori Joffe

Degree

MD

Center

N/A

Institution

Psychiatric Hospital of Kellokoski

Address

City or Town

Kellokoski

State or Province

N/A

Zip or Postal Code

4500

Country

Finland

Email Address

grigori.joffe@hus.fi